Abstract
BACKGROUND:
Prostate carcinoma is one of the most common malignant tumors in men older than 50 years of age and is characterized by a highly variable clinical course. Cyclin D1 proto-oncogene is an important regulator of G1 to S phase progression in many different cell types
AIM OF STUDY:
To study the expression of cyclin D1 in prostate adenocarcinoma, and to evaluate the relationship of this protein with clinicopathological features (histological grade, perineural invasion, and preoperative PSA level).
MATERIALS AND METHODS :
This is retrospective study including 50 cases, forty cases diagnosed histopathology as prostate adenocarcinoma and 10 cases as a benign prostatic hyperplasia. These cases were collected from laboratory department of AL Shaheed Ghazi ALhariri hospital from November 2018 to May 2019. Type of biopsy is a needle core biopsy.
RESULTS:
The immunohistochemical expression of cyclin D1 was negative in benign prostatic hyperplasia, while in prostate adenocarcinoma 52.5% were positive .There was significant correlation between histological grade of prostate adenocarcinoma and immunohistochemical expression of cyclin D1 There was no association between immmunohistochemical expression of cyclin D1 in prostate adenocarcinoma with the presence of perineural invasion, and the pre –operative PSA level.
CONCLUSION:
Cyclin D1 expressed in prostate carcinoma and not in benign prostate hyperplasia.
ma .
Keywords
10. Ahmed ES, Elnour LS, Hassan R, Siddig EE, Chacko ME, Ali ET, Mohamed MA, Munir A, Muneer MS, Mohamed NS, Edris AM. Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions. BMC research notes. 2020 ;13:1-6.
11. Emin O¨zbek BM, Mustafa O¨zbek, Su¨leyman Bu¨yu¨kberberMD. Cyclin-D1 protooncogen expression in prostate cancer.Turkish J Cancer 2000 ; 30.
12. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clinical Cancer Research. 2000 ;6:1891-95.
)
